Skip to content

Replimune Group REPL Interest Income

Interest Income at other companies

CG Oncology logo
CG OncologyCGON
$6.29M-18.8%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$5.35M-31.5%
Roivant Sciences logo
Roivant SciencesROIV
$41.18M-24.6%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$4.24M+47.6%
Incyte logo
IncyteINCY
$33.69M+46.9%
GRAIL, Inc. logo
GRAIL, Inc.GRAL
$7.99M+2.7%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterestAndDividend.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's interest income?
Replimune Group (REPL) reported interest income of $2.85M in Q4 2025.
How has Replimune Group's interest income changed year-over-year?
Replimune Group's interest income decreased by 44.6% year-over-year, from $5.14M to $2.85M.
What is the long-term trend for Replimune Group's interest income?
Over 3 years (2022 to 2025), Replimune Group's interest income has grown at a 278.3% compound annual growth rate (CAGR), from $390K to $21.12M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.